Evidence map›Paper›PMID 29921732›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer.

Chaofeng Mu, Xiaoyan Wu, Xinyu Zhou, Joy Wolfram, Jianliang Shen, Dechen Zhang, Junhua Mai, Xiaojun Xia, Ashley M Holder, Mauro Ferrari and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Chaofeng Mu *Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Xiaoyan Wu *Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Xinyu ZhouDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Joy WolframDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.ORCID 0000-0003-0579-9897
Jianliang ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Dechen ZhangDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Xiaojun XiaDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Ashley M HolderDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas. hshen@houstonmethodist.org.
Houston Methodist · USZhejiang Chinese Medical University · CN

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHANG, JENNY C-N · 2016 to 2020
$9.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA193880NCI NIH HHS U54 CA143837NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCombined Modality TherapyDocetaxelDrug Resistance, NeoplasmFemaleGoldHSP27 Heat-Shock ProteinsHumansHyperthermia, InducedMetal NanoparticlesMiceNeoplasm Recurrence, LocalNeoplastic Stem CellsTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysDocetaxelGoldHSP27 Heat-Shock Proteins

Identifiers

PMID29921732
PMCPMC6168413
OpenAlexW2809314187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.